feedback welcome

Pimozide-Lurasidone

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[draft revision][checked revision]
Line 2: Line 2:
| from = Pimozide
| from = Pimozide
| to = Lurasidon
| to = Lurasidon
-
| stop =  
+
| stop = {{StopStand}}
-
* '''Day 1-7:''' gradually reduce the dose of pimozide to 50% of the dose.
+
| start = {{StartStand}}
-
* '''Day 8-14:''' gradually reduce the dose of pimozide to 0% of the dose
+
| info =  
-
* '''Day 14:''' stop administration of pimozide.
+
{{RefSwitchToLurasidone}}
-
| start =  
+
| view = switchstandaardup en down.jpg
-
* '''Day 1-7:''' start administration of lurasidon in a dose of 40 mg/day.
+
-
* '''Day 8-14:''' increase the dose of lurasidon to 80 mg/day if necessary. Note: Continue the dose of lurasidone 40 mg/day if the patiënt is stable.<ref>[http://www.ncbi.nlm.nih.gov/pubmed/23473350 McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.]</ref> 
+
-
| info = {{caveQT}}
+
}}
}}

Revision as of 13:30, 16 March 2015

Pimozide
Type Antipsychotic
Group Diphenylbutylpiperidines
links
Medscape Pimozide
PubChem 16362
PubMed Pimozide
Kompas (Dutch) Pimozide
Wikipedia Pimozide
Lurasidone
Type Antipsychotic
Group Atypical AP
links
Medscape Lurasidone
PubMed Lurasidone
Kompas (Dutch) Lurasidone
Wikipedia Lurasidone

Switch medication from Pimozide to Lurasidon.

Nietinrijdenbord.png Stop Pimozide
Eenrichtingbord.png Start Lurasidon
Infobord.png More information
Nietinrijdenbord.png — Pimozide
Eenrichtingbord.png — Lurasidon

The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About